Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Updated Investor Presentation18-11-2022
18-11-2022
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Presentation18-11-2022
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We would like to inform you that an Investor Conference Call is scheduled to be held on Friday, November 18, 2022 at 4:00 P.M. (Indian Standard Time) to discuss the financial performance of the Company for the Quarter and Half year ended September 30, 2022 (Q2 of Financial Year 2022-2023).15-11-2022
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication dated November 15, 2022 - Unaudited Standalone & Consolidated Financial Results for the Quarter and Half year ended September 30, 202215-11-2022
Q2FY23 Quarterly Result Announced for Orchid Pharma Ltd.
Orchid Pharma announced Q2FY23 results: Revenue jumps 36% QoQ and 36% YoY EBITDA jumps 154% QoQ and 133% YoY Manish Dhanuka, Managing Director, Orchid Pharma, said, “Our revenues have seen a sharp uptick over the past year. We have focussed on increasing capacity utilisations while controlling costs. Owing to all the measures we took, bearing fruit, and a strong product pipeline, the results are a sign of positive things to come." Result PDF15-11-2022
Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Un-Audited Standalone and Consolidated Financial Results of the Company for period ended Sept. 30, 2022.14-11-2022
Orchid Pharma Ltd - 524372 - Appointment of Company Secretary and Compliance Officer
Appointment of Company Secretary and Compliance Officer w.e.f. November 14, 2022.14-11-2022
Orchid Pharma Ltd - 524372 - Approval Of The Un-Audited Financial Results Of The Company For Quarter And Half Year Ended Sept. 30, 2022.
Approval of the Un-Audited Financial results of the Company for quarter and half year ended Sept. 30, 2022.14-11-2022
Orchid Pharma Ltd - 524372 - Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Result For The Quarter And Half Year Ended September 30, 2022.
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 ,inter alia, to consider and approve Approval of Standalone and Consolidated Unaudited Financial Result for the quarter and half year ended September 30, 2022.07-11-2022